Infection, Immunity and Inflammation Section, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
Digital Research Environment, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
Front Immunol. 2018 Nov 5;9:2547. doi: 10.3389/fimmu.2018.02547. eCollection 2018.
Spectratyping assays are well recognized as the clinical gold standard for assessing the T cell receptor (TCR) repertoire in haematopoietic stem cell transplant (HSCT) recipients. These assays use length distributions of the hyper variable complementarity-determining region 3 (CDR3) to characterize a patient's T cell immune reconstitution post-transplant. However, whilst useful, TCR spectratyping is notably limited by its resolution, with the technique unable to provide data on the individual clonotypes present in a sample. High-resolution clonotype data are necessary to provide quantitative clinical TCR assessments and to better understand clonotype dynamics during clinically relevant events such as viral infections or GvHD. In this study we developed and applied a CDR3 Next Generation Sequencing (NGS) methodology to assess the TCR repertoire in cord blood transplant (CBT) recipients. Using this, we obtained comprehensive TCR data from 16 CBT patients and 5 control cord samples at Great Ormond Street Hospital (GOSH). These were analyzed to provide a quantitative measurement of the TCR repertoire and its constituents in patients post-CBT. We were able to both recreate and quantify inferences typically drawn from spectratyping data. Additionally, we demonstrate that an NGS approach to TCR assessment can provide novel insights into the recovery of the immune system in these patients. We show that NGS can be used to accurately quantify TCR repertoire diversity and to provide valuable inference on clonotypes detected in a sample. We serially assessed the progress of T cell immune reconstitution demonstrating that there is dramatic variation in TCR diversity immediately following transplantation and that the dynamics of T cell immune reconstitution is perturbed by the presence of GvHD. These findings provide a proof of concept for the adoption of NGS TCR sequencing in clinical practice.
谱型分析被公认为评估造血干细胞移植 (HSCT) 受者 T 细胞受体 (TCR) 库的临床金标准。这些检测方法使用高变互补决定区 3 (CDR3) 的长度分布来描述移植后患者的 T 细胞免疫重建情况。然而,尽管有用,但 TCR 谱型分析的分辨率明显有限,该技术无法提供样本中存在的个体克隆型的数据。高分辨率克隆型数据对于提供定量的临床 TCR 评估以及更好地理解临床上相关事件(如病毒感染或 GvHD)期间的克隆型动力学是必要的。在这项研究中,我们开发并应用了一种 CDR3 下一代测序 (NGS) 方法来评估脐带血移植 (CBT) 受者的 TCR 库。使用该方法,我们从 16 名 CBT 患者和 5 名在大奥蒙德街医院 (GOSH) 的对照脐带样本中获得了全面的 TCR 数据。对这些数据进行了分析,以提供 CBT 后患者 TCR 库及其组成的定量测量。我们不仅能够重现,还能够量化通常从谱型分析数据中得出的推论。此外,我们证明了 TCR 评估的 NGS 方法可以为这些患者免疫系统的恢复提供新的见解。我们表明,NGS 可用于准确量化 TCR 库多样性,并为样本中检测到的克隆型提供有价值的推断。我们对 T 细胞免疫重建的进展进行了连续评估,表明移植后 TCR 多样性存在明显差异,并且 GvHD 的存在会干扰 T 细胞免疫重建的动态。这些发现为在临床实践中采用 NGS TCR 测序提供了概念验证。